Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Petros Pharmaceuticals Inc PTPI

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment... see more

Recent & Breaking News (NDAQ:PTPI)

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider

ACCESS Newswire December 12, 2023

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider

ACCESS Newswire December 5, 2023

Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

ACCESS Newswire October 30, 2023

Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

ACCESS Newswire October 19, 2023

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label

ACCESS Newswire October 4, 2023

Petros Pharmaceuticals to Present at the LD Micro Main Event XVI

ACCESS Newswire September 28, 2023

Petros Pharmaceuticals Provides Letter to Shareholders

ACCESS Newswire September 11, 2023

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

ACCESS Newswire September 6, 2023

Petros Pharmaceuticals Announces Capital Raise of $15 Million

ACCESS Newswire July 13, 2023

Petros Pharmaceuticals Announces Reverse Stock Split

ACCESS Newswire November 30, 2022

Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update

ACCESS Newswire November 15, 2022

New FDA-Approved Labeling for Petros Pharmaceuticals' STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy

ACCESS Newswire October 25, 2022

Petros Pharmaceuticals to Participate in Two October 2022 Conferences

ACCESS Newswire October 21, 2022

Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy

ACCESS Newswire September 8, 2022

Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022

ACCESS Newswire August 15, 2022

Petros Pharmaceuticals Responds to Fraudulent Press Release

GlobeNewswire July 28, 2022

Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky

GlobeNewswire July 19, 2022

Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 16, 2022

Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US

GlobeNewswire May 3, 2022

Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022

GlobeNewswire April 27, 2022